digest
Short Summary
Main recommendation: Jocelyne Bloch argues that the injured adult brain can be helped to repair itself by reimplanting a patient's own cultured brain cells, an autologous graft, rather than only using neuromodulation such as deep brain stimulation. In her monkey studies, the reimplanted cells disappeared in healthy brains but matured into neurons in lesioned brains and improved recovery, and the approach is still awaiting human clinical trials.
Key Points
- Deep brain stimulation modulates neural circuits but does not repair the brain, which is the gap Bloch's team hopes to close.
- The cells came from superficial brain tissue removed during decompressive surgery on head-trauma patients, rather than from the rare stem cells deep in the brain.
- The cultured cells behaved like stem cells at first but divided slowly and eventually died after a few weeks, making them a distinct cell population.
- Doublecortin-positive cells, which make up about 4% of adult cortical brain cells and help the brain fold during fetal development, are the likely origin; their role in adult repair is not yet confirmed.
- In monkeys, reimplanted cells vanished in normal brains but survived and became mature neurons in lesioned brains, and monkeys with reimplanted cells improved their manual dexterity beyond their spontaneous recovery.
Details Worth Noting
- Concrete instructions: The method is to biopsy a small piece of brain tissue from a non-eloquent area, culture the cells in the lab with a nutrient, warmth, and humidity environment, label them with color so they can be tracked, and then reimplant them into the same individual. The cells can also be cryopreserved for later use, and the team has applied them to other models such as Parkinson's disease.
- The team's experiment compared a normal brain with a lesioned brain and tested fine motor function with a food-pellet retrieval task before and after the lesion and graft.
- Monkeys recovered only to about 40 to 50% of their pre-lesion performance spontaneously, and the reimplanted cells were associated with improved performance two months later.
- Bloch identifies regulation as the main obstacle, describing roughly two kilograms of paperwork before trials can start.
- Human trials would require approval, a small initial patient group, and then a multicenter study to prove both usefulness and safety before wider use; she gave no timeline.
Bottom Line
The approach is promising but still in the animal-research stage, and its path to patients depends on regulatory approval and multi-stage human trials that could take years.
